BXRXQ — Baudax Bio Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- $13.91m
- $1.27m
Brief: Baudax Bio Says Substantial Doubt Exists About Ability To Continue As A Going Concern For Next Twelve Months
Baudax Bio Inc expected to post a loss of 53 cents a share - Earnings Preview
Brief: Baudax Bio Says Phase 1/2a Clinical Study of TI-168 In Hemophilia A with FVIII Inhibitors Projected to Begin Q1 2024
Brief: Baudax Bio Inc - On October 5, 2023, Board Of Directors Of Company Appointed Natalie Mcandrew As Interim Chief Financial Officer
Baudax Bio Inc reports results for the quarter ended in June - Earnings Summary
Brief: Baudax Bio Q2 EPS continuing operations USD -1.49
Brief: Baudax Bio Posts Qtrly Loss Per Share $1.51
Baudax Bio Inc expected to post a loss of $2.04 a share - Earnings Preview
Brief: Baudax Bio Says Nasdaq Granted Request For Continued Listing
U.S. STOCKS ON THE MOVE-US banks, Circor
U.S. STOCKS ON THE MOVE-Bausch + Lomb, Apple Inc, Madrigal Pharma
U.S. STOCKS ON THE MOVE-Bright Health, Baudax Bio
Brief: Baudax Bio Acquires Teraimmune, Inc.
Brief: Baudax Bio Inc Files For Shelf Of Up To 785,402 Shares Of Common Stock By Selling Stockholder - SEC Filing
Brief: Baudax Bio Inc- On May 17, Received Delist Determination Letter From Nasdaq That Determined That Company Did Not Meet Terms Of Extension
Baudax Bio Inc reports results for the quarter ended in March - Earnings Summary
Baudax Bio Inc expected to post earnings of $5.79 a share - Earnings Preview
Baudax Bio plummets on stock-and-warrants deal
Brief: Baudax Bio Announces Pricing Of 3.5 Million Shares Of Its Common Stock At A Price Of $1.15 Per Share